Successful Retransplantation With Killer Cell Immunoglobulin-like Receptor Ligand-mismatched Cord Blood in Infant Acute Lymphoblastic Leukemia That Relapsed After Transplantation

J Pediatr Hematol Oncol. 2023 May 1;45(4):e547-e550. doi: 10.1097/MPH.0000000000002614. Epub 2023 Jan 9.

Abstract

The prognosis of children with KMT2A -rearranged ( KMT2A -r) acute lymphoblastic leukemia (ALL) remains dismal. This report describes the successful retransplantation of a patient with infant ALL who relapsed both bone marrow and central nervous system. The patient received HLA-matched cord blood transplantation (CBT) and relapsed 18 months later. After achieving the second remission, the patient received a killer cell immunoglobulin-like receptor ligand-mismatched CBT with a reduced-intensity conditioning regimen and has been in remission for 52 months. Thus, killer cell immunoglobulin-like receptor ligand-mismatched CBT with reduced-intensity conditioning might be a treatment option for patients with KMT2A- r ALL who relapsed after transplantation, even with extramedullary relapse.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Infant
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / surgery
  • Receptors, KIR
  • Treatment Outcome

Substances

  • Receptors, KIR
  • KMT2A protein, human